LAW
Rezolute Stock Crashes 90% After Phase 3 sunRIZE Trial Failure for Ersodetug in Hyperinsulinism
Rezolute; RZLT; ersodetug; Phase 3 failure; sunRIZE trial; stock crash; hyperinsulinism
AC Immune Reports Promising Phase 2 Interim Data for Parkinson’s Immunotherapy ACI-7104.056
AC Immune; ACI-7104.056; Parkinson’s disease; Phase 2 trial; alpha-synuclein; biomarker stabilization
Ventus Therapeutics Doses First Patient in Phase 2 Trial of VENT-03, an Oral cGAS Inhibitor, in Lupus
Ventus Therapeutics; VENT-03; cGAS inhibitor; Phase 2 trial; lupus; cutaneous lupus erythematosus; autoimmune disease; interferon pathway; biomarkers; oral small molecule; clinical trial; immunology; cardiometabolic; inflammaging
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig in Advanced Triple-Negative Breast Cancer
BioNTech; Bristol Myers Squibb; pumitamig; BNT327; PD-L1xVEGF-A bispecific antibody; Phase 2 trial; triple-negative breast cancer; TNBC; confirmed ORR; disease control rate; progression-free survival; PD-L1 expression; ROSETTA BREAST-01; SABCS
Rapport Therapeutics Reports Updated Phase 2a Data for Seizure Drug RAP-219
Rapport Therapeutics; RAP-219; Phase 2a trial; seizure drug; epilepsy; focal onset seizures; clinical seizure reduction; FDA meeting; Phase 3 trials
Capricor Therapeutics Reports Positive Phase 3 HOPE-3 Trial Results for Deramiocel in Duchenne Muscular Dystrophy, Planning FDA Resubmission
Capricor Therapeutics; Deramiocel; Duchenne muscular dystrophy; HOPE-3 trial; Phase 3 clinical trial; FDA rejection; cardiac function preservation; upper limb function; clinical trial results; regulatory approval pathway
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at CTAD Conference
Cognition Therapeutics; Zervimesine; CT1812; Phase 3 clinical trial; Alzheimer’s disease; Clinical Trials on Alzheimer’s Disease (CTAD); neurodegenerative diseases; sigma-2 receptor; dementia with Lewy bodies; expanded access program
RapidAI Deepens Partnership with Amazon AWS to Expand Clinical Imaging AI Deployment
RapidAI; Amazon Web Services; AWS; clinical AI; imaging AI; RSNA 2025; FDA clearance; Rapid Edge Cloud; healthcare AI; neurovascular AI; Lumina 3D
CMS Unveils Negotiated Prices for Ozempic, Wegovy, and Other Drugs in Second Round of IRA Talks
CMS; Ozempic; Wegovy; Inflation Reduction Act; drug price negotiation; Medicare Part D; semaglutide; negotiated prices; 2027 effective date
Pharma Faces Supreme Court Deadline as IRA Price Negotiation Takes Effect
Inflation Reduction Act; SCOTUS; drug price negotiation; AstraZeneca; Medicare; pharmaceutical lawsuits; Fifth Amendment; supreme court petition; Farxiga; Centers for Medicare & Medicaid Services; price controls